

## IRREVERSIBLE INHIBITION OF BEEF LIVER VALYL-tRNA SYNTHETASE BY AN ALKYLATING DERIVATIVE OF L-VALINE

L.Yu. FROLOVA, G.K. KOVALEVA, M.B. AGALAROVA and L.L. KISSELEV

*Institute of Molecular Biology, USSR Academy of Sciences, Moscow 117312, USSR*

Received 20 February 1973

Revised version received 19 March 1973

### 1. Introduction

Pseudosubstrates containing chemically reactive groups allow valuable information about the catalytic centres of enzymes to be obtained. Halogenomethylketones, inhibitors which retain the main structural features of substrates as well as possessing pronounced alkylating properties, have given good results. They have been used to demonstrate the role of histidine residues in trypsin and  $\alpha$ -chymotrypsin [1, 2] and the essential nature of SH-groups in papain and carbamoyl-phosphate synthetase [3, 4].

Because of these and other observations it looked promising to use this type of irreversible inhibitor to investigate the active centres of aminoacyl-tRNA synthetases (EC 6.1.1). The carboxyl group of the substrate amino acid is not essential for binding to these enzymes [see 5] and it may therefore probably be substituted by an alkylating group without preventing binding.

It is shown here that L-3-amino-1-chloro-4-methylpentan-2-one (chloromethylketone), an analogue of L-valine, is an irreversible inhibitor of valyl-tRNA synthetase.

### 2. Materials and methods

#### 2.1. Enzymes and tRNA

Total tRNA was isolated from beef liver [6]. Highly purified beef liver valyl-tRNA synthetase was obtained by the procedure in [7] with modifications to be described elsewhere. The preparation contained traces of some other synthetases and some other proteins.

#### 2.2. Activity measurement

Enzyme activity was measured by the initial rate (5 min, 30°C) of aminoacylation of total tRNA with [ $^{14}$ C]valine. The incubation mixture (0.2 ml) contained (in  $\mu$ moles): Tris-HCl, pH 7.5, 10;  $MgCl_2$ , 4; KCl, 4; ATP, 0.6; L-valine, 0.01; in addition, human serum albumin 0.05 mg; tRNA 0.05–0.1 mg and a rate-limiting amount of valyl-tRNA synthetase. L-[ $^{14}$ C]-valine (100–130 Ci/mole) was from the Institute for Isotope Research (Czechoslovakia), ATP (Na-salt) from Reanal (Hungary). The reaction was stopped by addition of 0.2 ml cold 10% trichloroacetic acid, precipitates were collected on nitrocellulose filters (RUFS, Chcmapol, Czechoslovakia), washed with cold 5% trichloroacetic acid and counted in an Intertechnique SL-30 scintillation counter.

Activity in the presence of L-valine methyl ester and of L-3-amino-4-methylpentan-2-one (methylketone) was measured in the same way.

#### 2.3. Inhibition

The rate of irreversible inhibition was followed by assaying activity (as in 2.2.) in samples at different times after mixing enzyme and inhibitor. The inhibitors, chloromethylketones, L-valine and L-aspartate analogues, were incubated with enzyme in 0.05 M K-phosphate buffer, pH 7.5 at 25°C. The kinetic constants of inhibition were determined with a 100-fold concentration excess of inhibitor over enzyme.

#### 2.4. Test for possible reactivation

Enzyme (3 mg/ml) was incubated for 5 hr in the presence of  $5 \times 10^{-4}$  M chloromethylketone or methylketone as in 2.3. Aliquots were diluted 100-fold and

assayed as in 2.2. or aliquots were assayed after passing through a Sephadex G-25 (fine) column (1 X 20 cm) equilibrated with 0.05 M K-phosphate buffer, pH 7.5, to remove excess inhibitor. The activities were compared with that of enzyme subjected to the same procedure but without inhibitor.

### 2.5. Syntheses

For the synthesis of 3-amino-1-chloro-4-methylpentan-2-one (chloromethylketone), *N*-carbobenzoxy-L-valine [8], isobutyl chloroformate [9] and diazomethane [10] were prepared. A solution of 1.2 g (5 mmol) of *N*-carbobenzoxy-L-valine in 10 ml dry ethyl acetate was treated at  $-5^{\circ}\text{C}$  with 0.7 ml (5 mmol) triethylamine and 0.68 ml (5 mmol) isobutyl chloroformate. After 5 min the triethylammonium chloride formed was removed and 10 ml (0.88 N) of a solution of diazomethane in dry ether were added. The mixture was shaken for 3 hr at  $0^{\circ}\text{C}$  and left to stand for 10 hr. It was then washed at  $4^{\circ}\text{C}$  with water, 5%  $\text{NaHCO}_3$ , washed again and dried over anhydrous  $\text{Na}_2\text{SO}_4$ . After removal of half the solvent, light petroleum was added to initiate crystallization of diazoketone, the yield of which was 0.66 g (50%), m.p.  $77-78^{\circ}\text{C}$ , IR spectrum (in KBr) had bands at  $2120\text{ cm}^{-1}$  ( $-\text{N}_2$ ) and  $1715\text{ cm}^{-1}$  ( $-\text{C}=\text{O}$ ).

Hydrogen chloride gas was passed into a solution of 0.265 g (1 mmol) diazoketone in 10 ml dry ether for 30 min at  $4^{\circ}\text{C}$ . After removal of the ether, the residue was dried *in vacuo* over NaOH. Two ml 37% HBr in glacial acetic acid was added and the mixture shaken for 40 min at  $20^{\circ}\text{C}$ . After addition of 5 ml dry ether the flask was allowed to stand for 12 hr at  $4^{\circ}\text{C}$ . The solution was then decanted and the precipitate washed several times with petroleum in the cold and dried *in vacuo* over  $\text{P}_2\text{O}_5$  and NaOH. Yield 0.15 g (55%), m.p.  $80-82^{\circ}\text{C}$ , IR spectrum (in KBr) had a band at  $1733\text{ cm}^{-1}$  ( $-\text{C}=\text{O}$ ), electrophoretic mobility  $1.05 \times 10^{-4}\text{ cm}^2/\text{sec/V}$ .

L-3-amino-4-methylpentan-2-one (methylketone) was prepared by reduction of chloromethylketone on Pd/C with close to a quantitative yield, m.p.  $99-100^{\circ}\text{C}$ , electrophoretic mobility  $1.4 \times 10^{-4}\text{ cm}^2/\text{sec/V}$ .

2-Amino-4-keto-5-chloropentanoic acid was prepared starting from the  $\alpha$ -benzyl ester of *N*-carbobenzoxy-L-aspartic acid [12] by the method used above for chloromethylketone L-valine analogue. To effect the simultaneous removal of the  $\alpha$ -benzyl group and the carbobenzoxy group, treatment with 37% HBr in

glacial acetic acid was extended to 12 hr. The product was purified by preparative electrophoresis, m.p.  $151-152^{\circ}\text{C}$  [4], electrophoretic mobility  $1.3 \times 10^{-4}\text{ cm}^2/\text{sec/V}$ . L-valine methyl ester was prepared as in [11].

Analytical electrophoresis was in pyridine-acetic acid-water (1:10:189, v/v), pH 3.5, potential gradient 100 V/cm, FN12 paper, with cooling. The same system was used for preparative electrophoresis but with Whatman 3 MM paper and 80 V/cm for 2 hr. All substances prepared were characterized by elemental analysis; the values found corresponding with theoretical ones to within the limits of accuracy of the methods used.

### 3. Results

The dependencies of the reaction velocities on L-valine concentration with various concentrations of carboxyl-substituted L-valine analogues, plotted in Dixon's co-ordinates [13], are shown in fig. 1. The inhibition is evidently competitive and reversible and in accord with similar data for *E. coli* valyl-tRNA synthetase with some other analogues [14]. The  $K_i$  values, obtained graphically from the data in fig. 1, are  $4 \times 10^{-4}\text{ M}$  for the methyl ester and  $3 \times 10^{-4}\text{ M}$  for the methylketone, whereas with L-valine  $K_m = 7 \times 10^{-6}\text{ M}$ . Since both methylketone and L-valine methyl ester have high affinities for the enzyme, low  $K_i$  values, it is reasonable to expect that chloromethylketone will also have a considerable affinity and,




Fig. 1. The effect of methylketone, an analogue of L-valine (A) and L-valine methyl ester (B) on the formation of valyl-tRNA catalyzed by valyl-tRNA synthetase from beef liver. Concentrations of L-valine are  $\mu\text{M}$ .




Fig. 2. The dependence of activity of valyl-tRNA synthetase on the time of incubation with chloromethylketone, an analogue of L-valine: A) Inhibitor concentrations are mM. Y-axis is logarithmic. Concentration of the protein, 0.6 mg/ml; B) The dependence of  $k_{app}$  on concentration of chloromethylketone, an analogue of L-valine (calculated from fig. 2A).

because of its alkylating ability, will act as an irreversible inhibitor. As is shown in fig. 2, chloromethylketone does indeed cause a progressive inhibition of the enzyme, even in low concentrations. During the first hours L-valine has a protective action against chloromethylketone inhibition (table 1).

No reactivation was observed after gel-filtration of the enzyme-chloromethylketone complex and treatment with excess L-valine. A 100-fold dilution of the enzyme-methylketone complex led to almost complete restoration of enzyme activity while it had no effect on the enzyme-chloromethylketone complex. The chloromethylketone analogue of aspartic acid, 2-amino-4-keto-5-chloropentanoic acid, at  $10^{-4}$  M caused no inactivation of the enzyme. Since all the evidence points to an irreversible inhibition by the chloromethylketone analogue of L-valine, a further kinetic analysis by the method of Kitz and Wilson [15] was made. The reaction scheme for the formation of the alkylated enzyme ( $E'I$ ) is:




Table 1

The influence of preincubation with chloromethylketone, an analogue of L-valine, on the activity of valyl-tRNA synthetase in the absence or presence of L-valine.

Chloromethylketone (M)	L-Valine (M)	Residual activity, %		
$\begin{array}{c} \text{CH}_3 \\ \diagup \\ \text{CH}-\text{CH}-\text{COCH}_2\text{Cl} \\ \diagdown \quad \parallel \\ \text{CH}_3 \quad \text{NH}_2 \end{array}$		Time of preincubation with inhibitor (hr)		
		1	2	4
$5 \times 10^{-5}$		90	85	73
$5 \times 10^{-5}$	$5 \times 10^{-5}$	100	100	80
$5 \times 10^{-4}$		35	16	10
$5 \times 10^{-4}$	$5 \times 10^{-4}$	100	45	35

where  $E'I$  is a reversible enzyme-inhibitor complex and  $k_2$  the rate constant for the conversion of  $E'I$  into  $E'I$ .

Semilogarithmic plots of the degree of inactivation with time (fig. 2A) are straight lines, showing pseudo-first-order kinetics. The half-time of conversion of  $E'I$  into  $E'I$  ( $t_{1/2}$ ) and the first-order rate constants for irreversible inactivation ( $k_{app}$ ) at each inhibitor concentration may be calculated from fig. 2A. A reciprocal plot of  $k_{app}$  against inhibitor concentration is shown in fig. 2B, the positive intercept on the Y-axis shows that formation of the reversible complex  $E'I$  preceeds that of the irreversible complex  $E'I$ . From fig. 2B,  $k_2$  ( $0.02 \text{ min}^{-1}$ ) and  $K_i$  may be calculated. The approximate value of  $K_i \approx 7 \times 10^{-4} \text{ M}$  found is close to the values for methylketone and L-valine methyl ester.

With high concentrations of chloromethylketone ( $\geq 10^{-3} \text{ M}$ ), deviations from the pattern characteristic of simple irreversible inhibition were observed, probably due to alkylation reactions with additional SH-groups.

#### 4. Discussion

The data presented here provide evidence that chloromethylketone, and alkylating analogue of L-valine, is an irreversible inhibitor of beef liver valyl-tRNA synthetase. The inhibition develops progressively with time, no reactivation occurs after removal of excess inhibitor and addition of high concentrations

of substrate and the kinetic pattern is characteristic of irreversible inhibition.

Alkylation involves a region of the molecule important for its catalytic function, probably the substrate-binding site because L-valine protects against inactivation and the kinetics of inhibition show involvement of the active site, inhibition occurs even at low inhibitor concentrations at which the rate of alkylation outside the catalytic centre is usually low and another alkylating derivative, the analogue of L-aspartic acid, does not inactivate the enzyme at similar concentrations.

The present work opens up the way to specific affinity labelling of aminoacyl-tRNA synthetases with halogenmethylketone analogues of their substrate amino acids.

#### Acknowledgements

The authors are indebted to Professor W.A. Engelhardt and Drs. A.A. Krayevsky and E.S. Severin for valuable criticism.

#### References

- [1] Shaw, E. (1970) in: *The Enzymes* (Boyer, P.D., ed.), Academic Press, New York, Vol. 1, p. 91.
- [2] Shaw, E.S. (1970) *Physiol. Rev.* 50, 244.
- [3] Hussain, S.S. and Lowe, G. (1965) *Chem. Commun.* 15, 345.
- [4] Pinkus, L.M. and Meister, A. (1972) *J. Biol. Chem.* 247, 6119.
- [5] Mehler, A.H. and Chakraborty, K. (1971) in: *Advances in Enzymology* (Meister, A., ed.), Vol. 35, p. 443, Intersciences Publishers, New York.
- [6] Rogg, H., Wehrli, W. and Staehelin, M. (1969) *Biochim. Biophys. Acta* 195, 13.
- [7] Yoshida, S., Tada, M., Nischigaki, I. and Yagi, K. (1969) *J. Biochem.* 65, 27.
- [8] Wunsch, E. (1958) *Chem. Ber.* 91, 449.
- [9] Vaughan, J.R. and Osato, R.L. (1952) *J. Am. Chem. Soc.* 74, 676.
- [10] Arndt, F. and Amende, S. (1933) *Angew. Chem.* 46, 47.
- [11] Boissonnas, R.A., Guttmann, St., Jaquenoud, P.-A. and Waller, J.-P. (1956) *Helv. Chim. Acta* 39, 1421.
- [12] Goldschmidt, S. and Jutz, C. (1953) *Chem. Ber.* 86, 1116.
- [13] Dixon, M. (1953) *Biochem. J.* 55, 170.
- [14] Owens, S.L. and Bell, F.E. (1970) *J. Biol. Chem.* 245, 5515.
- [15] Kitz, R. and Wilson, I.B. (1962) *J. Biol. Chem.* 237, 3245.